How can industry and academia work together in a way that respects each other’s needs (freedom to publish vs. IP; conflict-of-interest; funding goals)? What is the role of the Technology Transfer Office?
Possible solutions. New paradigms of drug development: New discovery models; new translational models. Role of academic industry partnerships. Role of the NIH and the “Collins Initiative:” National Center for Advancing Translational Sciences (NCATS).
Will payers and their agents like NICE kill the goose that lays golden eggs of innovation, or will the demand for proven better outcomes as compared to current standard of care, lead to new alignments of manufacturers, providers and payers? Will governments, taking an ever larger role in providing both incentives and mandates, drive change that supports or inhibits innovation?
Are the incentives to develop new devices misaligned with the need to control costs.? What is the right balance between incremental innovation and major innovation and how will regulatory policy evolve as a solution?